Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.30 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18656790 | 0.77 | MEN1 (0.36) | ALDH1A1LMNA | |
| SCHEMBL18640848 | 0.75 | ADORA2A (0.33) | HSD17B10CNR1CNR2ALDH1A1LMNA | |
| SCHEMBL18640818 | 0.74 | NPC1 (0.38) | — | |
| SCHEMBL5764846 | 0.67 | GPR4 (0.44) | ALDH1A1LMNA | |
| SCHEMBL25456980 | 0.66 | ADORA2A (0.31) | ALDH1A1LMNA | |
| SCHEMBL31138633 | 0.63 | MAPT (0.37) | — | |
| SCHEMBL31138646 | 0.63 | MAPT (0.37) | — | |
| SCHEMBL29910281 | 0.62 | TLR7 (0.36) | HSD17B10ALDH1A1LMNA | |
| SCHEMBL23326542 | 0.62 | TLR7 (0.36) | HSD17B10ALDH1A1LMNA | |
| SCHEMBL29910267 | 0.62 | KDM4E (0.35) | HSD17B10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180237441-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| EP-3350185-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2018-07-25 | — | — | EP | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017046737-A1 | 1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237441-A1 | Chemical Compounds | PSEN1, IRS1, CPT1A | HSD17B10 3219/4885CNR1 360/4885CNR2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.